



Studies of catechol-functionalized multidentate block copolymer strategy to 





A thesis in the Department of Chemistry and Biochemistry 
 
Presented in Partial Fulfillment of the Requirements for the Degree of 
Master of Science (Chemistry) at 
Concordia University  
Montreal, Quebec, Canada 
November 2015 




School of Graduate Studies 
This is to certify that the thesis prepared 
By: Puzhen Li 
Entitled: Studies of catechol-functionalized multidentate block copolymer strategy to stabilize 
superparamagnetic iron oxide nanoparticles for magnetic resonance imaging 
and submitted in partial fulfillment of the requirements for the degree of 
Master of Science (Chemistry) 
complies with the regulations of the University and meets the accepted standards with respect to 
originality and quality. 
Signed by the final Examining Committee: 
_________________________________Chair 
 Dr. Louis Cuccia                                       Examiner 
Dr. Xavier Ottenwaelder                           Examiner 
Dr. Jung Kwon (John) Oh                               Supervisor 
Approved by       ______________________ Chair of Department or Graduate Program Director 





Studies of catechol-functionalized multidentate block copolymer strategy to 
stabilize superparamagnetic iron oxide nanoparticles for magnetic resonance 
imaging  
Puzhen Li 
Magnetic resonance imaging (MRI) contrast agents play important roles in diagnosis and 
clinical applications. Particularly, superparamagnetic iron oxide nanoparticles (SNPs) with 
appropriate surface modification hold enormous promise as MRI contrast agents owning to their 
excellent biocompatibility. This thesis describes novel catechol-functionalized multidentate 
block copolymer (Cat-MDBC) strategy that enables the stabilization of SNPs with diameter ≤3.5 
nm as effective MR bright imaging (T1-weighted) contrast agents. 
Atom transfer radical polymerization and post-modification methods allow for the synthesis 
of well-controlled Cat-MDBCs. They enable the stabilization of ultrasmall SNPs with diameter 
≈3.5 nm (i.e. USNPs) through a biphasic ligand exchange process. The results from surface 
characteristics, colloidal stability in physiological properties, relaxivity properties, and in vitro 
MRI suggest that the USNPs coated with Cat-MDBC (Cat-MDBC/USNPs) can be a promising 
candidate for T1-MRI application.  
Further, extremely small SNPs with diameter ≈2 nm (i.e. ESNPs) coated with Cat-MDBC 
(Cat-MDBC/ESNPs) have better relaxivity properties as T1-MRI contrast agents, compared with 
the Cat-MDBC/USNP colloids; and more promisingly, they have the r2/r1 value comparable to 
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Chapter 1: Introduction 
1.1  Summary 
The main objective of this M.Sc research is to exploit a novel multidentate block copolymer 
(MDBC) strategy to stabilize superparamagnetic iron oxide nanoparticles (SNPs) as effective 
magnetic resonance imaging (MRI) contrast agents with prolonged colloidal stability. Atom 
transfer radical polymerization (ATRP), a well-known controlled radical polymerization method 
(CRP), was employed to synthesize well-defined MDBCs having pendant catechol groups that 
anchor to SNPs surfaces. The resultant Cat-MDBCs were proved to be effective to yield aqueous 
Cat-MDBC/SNP colloids with hydrodynamic diameter <20 nm. The Cat-MDBC/SNPs were 
further characterized for colloidal stability, surface properties and magnetic properties including 
relaxivity and in vitro MRI. These results indicate that MDBC-stabilized SNPs can be promising 
candidates for MRI contrast enhancement. 
1.2  MRI contrast agents  
1.2.1  General background of MRI contrast agents 
Over the last forty years since MRI was firstly reported in 1973,1  it has become one of the 
most important imaging techniques in clinic use. Compared to other imaging techniques such as 
X-ray Computed Tomography utilizing ionizing radiation, MRI has been considered as a 
radiation-free imaging technique which is applicable to imaging bone and soft tissues.2 In fact, 
the principle of MRI is similar to nuclear magnetic resonance (NMR) spectroscopy. In magnetic 
field under irradiation of resonant radiofrequency, the nuclei with different relaxometric 
properties (e.g. relaxation time) generate NMR signals with different intensities, which can be 
decoded into dark and bright MR images. 2 However to obtain high spatial resolution, the use of 
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MRI contrast agents is necessary.3 Paramagnetic and superparamagnetic metal ions in the 
contrast agents change MRI signals of tissues. Reports suggest the use of MRI contrast agents to 
be greater than 35% of clinical MRI scans.4 
1.2.2  Paramagnetic contrast agents 
Paramagnetic agents contain paramagnetic ions such as gadolinium (Gd3+) or manganese 
(Mn2+). The unpaired electrons in paramagnetic ions (for example, Gd3+ has seven unpaired 
electrons) can create permanent magnetic moment that can interact with small magnetic 
moments of the surrounding protons, usually water protons. Under the influence of this dipolar 
magnetic interaction, both longitudinal (T1) and the transverse (T2) relaxation times of these 
protons decrease.3 Owing to their high efficiency in decreasing proton relaxation times, Gd3+-
based contrast agents have been widely used for T1-weighted (bright) MRI.
5 However, several 
concerns for Gd3+-based contrast agents include their undesired bioaccumulation, toxicity and 
potential role in causing nephrogenic systemic fibrosis (NSF), a severe even fatal systemic 
disease observed in patients with history of Gadolinium-based contrast agents administration, 
especially those with renal diseases.6-8 
1.2.3  Superparamagnetic iron oxide nanoparticles (SNPs)  
Iron oxide nanoparticles (usually <200 nm in diameter) are presented as superparamagnetic 
contrast agents which contain small crystallites with several thousand magnetic ions. 
Superparamagnetic nanoparticles do not have permanent magnetic moment without external 
magnetic field, because thermal energy averages the direction of the total magnetization of the 
crystallite. In the presence of the external magnetic field, however, these superparamagnetic 
agents exhibit high saturation magnetization.9 Compared to paramagnetic ions, these magnetic 
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nanoparticles have larger magnetic moment and therefore can be effective at much lower doses 
(around µmol/kg body weight).3, 10 SNPs are biologically tolerated and biocompatible, because 
iron ions generated through macrophage uptake and lysosome degradation can be incorporated 
into body iron store such as ferritin and hemosiderin.9, 11 In another aspect, since the 
superparamagnetic nanoparticles can be internalized into phagocytic cells like macrophages, the 
detection of internalized contrast agents can reveal the macrophage phagocytic activity; therefore 
benefiting the early diagnosis of inflammatory diseases such as atherosclerosis.12 The fact that 
the superparamagnetic iron oxide agents can be designed for long circulation time also allows for 
the imaging of the lymphatic vessels, nodal architecture or targeted imaging.13 
SNPs are generally designed as T2-contrast agents providing dark imaging in T2-weighted 
MRI. Recent advance is the development to synthesize well-defined, uniform sized, ultrasmall 
(diameter <10 nm) or even extremely small (diameter <3 nm) iron oxide nanoparticles (USNPs 
and ESNPs). The magnetic moment of iron oxide nanoparticles is proportional to their volume 
and thus individual particle has very small magnetic moment. (For example, the magnetic 
moment of ESNPs with diameter = 1.5 nm is estimated to be 3.91µB).
9 Consequently, USNPs  
and ESNPs with small magnetic moment exhibit almost linear relationship between 
magnetization and magnetic field, which is similar to the magnetic property of paramagnetic 
materials.9 Therefore, they can be used as T1-contrast agents, providing bright MR imaging. 
1.3  Surface modification of SNPs 
Bare SNPs are easily precipitated to form aggregates due to hydrophobic interactions and 
magnetic attractions. Hydrophobic stabilizers such as oleic acid (C18H34O2) are broadly used in 
synthesis of SNPs to control the particle size and size distribution. These hydrophobic coatings 
need to be changed to be hydrophilic ones for biological and biomedical applications, especially 
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as blood pool contrast agents. Different types of coatings or stabilizers have been designed and 
explored for surface modification of SNPs. In general, they can be classified as non-polymer and 
polymer stabilizers based on the number of repeating unit in individual stabilizer. 
1.4  Non-polymer stabilizers 
1.4.1 Silica 
Silica coating can prevent aggregation, protect nanoparticle core and avoid the unwanted 
direct interaction of functional agents with SNP surfaces. Silica coatings are hydrophilic, easy 
for the modification with other functional groups, and have tunable thickness.14, 15 Stὄber method 
enables to form in situ silica coatings through hydrolysis and condensation of sol–gel precursor. 
The variation of the coating thickness was achieved by changing the concentration of ammonium 
and the ratio of tetraethoxysilane/H2O.
14, 16  Microemulsion method involves the formation of 
microemulsions of SNPs confined in silica shells (1.8 - 30 nm).17 Although silica coating has 
been widely used for surface modification of nanoparticles, the lack of stability of silica in basic 
environments sometimes limits its use. 
1.4.2  Precious metals 
To protect magnetic nanoparticles from oxidation, precious metals such as gold can be used 
as the coating material, owning to their chemical inertness. A number of synthetic methods to 
synthesize precious metal coated magnetic nanoparticles have been reported, including redox 
transmetalation18 and microemulsion,19 which are air stable and dispersible in organic solvent or 
even in aqueous solution. The novel gold coated SNPs were synthesized by partial replacement 
reaction—use of reducing agents such as Li, Na and K to reduce FeCl2 to form metallic core 
particles with diameter ≈11 nm, which can then reduce Au3+ to form gold coating with 
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thickness = 2.5 nm.20 Further, the Au-coated magnetic nanoparticles have been explored as 
multifunctional contrast agents for both magnetic and dual optical applications.21 This can be 
achieved by functionalization of  Au surface with thiols.22 
1.4.3  Small molecules 
 Small molecules functionalized with anchoring groups such as carboxylates, phosphates 
and catechols that can bind to the surfaces of SNPs are used as stabilizers. For the small 
molecules with carboxylate groups, oleic acid is the commonly-used stabilizer for the synthesis 
of SNPs. It allows for the synthesis of monodisperse, well-controlled SNPs and USNPs.23, 24 
Other carboxylates include citric acid,25, 26  gluconic acid 27 and dimercaptosuccinic acid.28 
However these carboxylate based stabilizers exhibit a drawback that is the colloidal stabilities of 
SNPs stabilized with these stabilizers significantly rely on pH or ionic strength of aqueous 
environments.29  
  Phosphate-based small molecules are also used to stabilize SNPs.30-32 A report compares 
the properties of magnetic nanoparticles coated with different surfactants including oleic acid, 
lauric acid, hexadecyl phosphate, and dihexadecyl phosphate.30 The results obtained for 
transmission electron microscope, thermogravimetric and differential scanning calorimetry 
measurements suggest that magnetic nanoparticles coated with carboxylate surfactants have 
better dispersibility in nonpolar organic solvent, while those coated with phosphate surfactants 
are more thermodynamically stable.30  
 Besides carboxylates and phosphates, another type of promising anchoring group is 
catechol, which can form highly stable complex with iron (III) ion.  As seen in Fig 1.1 the 
stability constant is 1044.9 of [Fe(cat)3]
3- (octahedral complex formed by Fe3+ and three catechol 
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ligands), which is larger than that of [Fe(ox)3]
3− (tris-oxalate complex,  stability constant is 
1018.49).33 Such highly stable interaction between catechol and Fe(III) has been utilized to 
synthesize catechol based stabilizers for SNPs. For example, dopamine and 
dihydroxybenzaldehyde have been used to replace original diethylene glycol ligands on SNP 
surfaces to improve their colloidal stability in aqueous solution.34 Biotin functionalized 
dopamine (Fig. 1.1d) has also been used to modify the SNP surfaces. The resulting SNPs were 
treated with fluorescein isothiocyanate (FITC)-labeled streptavidin, resulting in fabrication of 
fluorescent and magnetic responsive SNPs which are useful for protein binding, pathogen 
detection and molecular imaging.35 
 
Figure 1.1.  a) [Fe(cat)3]
3-,33  b) [Fe(ox)3]
3−,36  c) dopamine,  dihydroxybenzaldehyde,34 and d) 




1.5  Polymer coating 
 Apart from non-polymer stabilizers mentioned above, polymer coatings also have aroused 
researchers’ interest world-wide, owing to their tunable size and great possibilities for further 
functionalization. Many polymers such as dextran,37-41polyethylene glycol (PEG),42-46  polyvinyl 
alcohol (PVA) 47 and poly(oligo (ethylene oxide) monomethyl ether methacrylate) (POEOMA)48 
have been synthesized and explored for magnetic nanoparticle stabilization. 
1.5.1  Dextran 
 Dextran is a biocompatible polysaccharide with various chain lengths; thus it has been 
broadly used as stabilizers for commercially-available, clinically-used SNPs contrast agents such 
as Feridex, Resovist and Ferumoxtran-10.39 Dextran coating can improve the hydrophilicity and 
stability of magnetic nanoparticles; it also provides prolonged blood circulation time because it 
decreases the non-specific interaction with plasma components.37 Such prolonged blood 
circulation is highly desirable when contrast agents are designed for imaging for target tissues, 
because they could have enough time to reach the target tissues or organs.    
A report describes the synthesis of dextran-coated SNPs through in situ coating for the 
formation of ferromagnetic iron-dextran particles (with diameter = 30 – 40 nm) by mixing 
ferrous chloride, ferric chloride and dextran (MW = 40000 g/mol) under alkaline conditions.38 
Further the reduction of terminal sugar moieties in dextran improve the stability of dextran-
coated SNPs.40 Another report describes the synthesis of SNPs with diameter = 5 nm  by laser 
pyrolysis, followed by their stabilization with dextran (MW = 6000 g/mol) by sonication for 24 
hrs at room temperature under basic conditions.41  
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1.5.2  Polyethylene glycol (PEG) 
PEG is well-known to have a number of great features such as hydrophilicity, low toxicity, 
good biocompatibility and no immunogenicity. They are highly desirable for biological and 
pharmaceutical applications.49 Thus,  PEG coating can prevent aggregation of nanoparticles, 
improve colloidal stability in aqueous solution, and decrease the non-specific interactions with 
proteins or cell surfaces.43 For example, PEG-phosphate (phosphate esterified PEG, Mw = 2000 
or 750) has been used to replace the original oleate coating on the surface of SNPs through a 
process called ligand exchange as shown in the Fig. 1.2. The colloid after ligand exchange can be 
stable in aqueous solution at neutral or acidic pH.44, 45 However, in PBS or basic condition, 
aggregations are quickly observed, probably owing the detachment of PEG-phosphate ligands 
from the nanoparticles.45 Similar design of PEG with carboxylic groups on one end was 
reported.50 The stability of the nanoparticles coated with this ligand are quite limited and can 
only be stable in aqueous solution for one day.50 Another type of PEG ligand design is to connect 
PEG to another block having multiple anchoring groups for improved colloidal stability. For 
example, using block copolymer polyethylene glycol-b-polyacrylic acid (PEG-b-PAA) (Mw = 
5000/3200) as the coating material for nanoparticles.46 Based on the dynamic light scattering 
results, the PEG-b-PAA coated nanoparticles remain stable at Tris-HCl buffer (pH = 7.4) for 
seven days. However, the end-group functionalized PEG precursors are usually difficult to 





Figure 1.2. Scheme of the ligand exchange reaction of oleate-coated SNP with PEG-phosphate.  
 
1.5.3 Polyvinyl alcohol (PVA) 
 Polyvinyl alcohol coatings are also explored by several research groups. For example, by 
directly precipitating the iron salts inside porous PVA matrices, researchers synthesized 
polymer-coated iron oxide nanoparticle.47 The influences of polymer/iron mass ratio on the 
resulting particle sizes and colloidal stability were further studied. According to the results, the 
colloidal stability of PVA coated iron oxide nanoparticle at pH 7 increases with polymer ratio, 
probably owing to the sufficient coating of nanoparticles.47 Other applications of PVA-stabilized 
iron oxide nanoparticles such as magnetic gels and magnetic films have also been reported.52 For 
example, researchers introduced ferrofluid to the PVA solution, used glutharaldehyde (GTA) as 
cross-linking agents to form magnetic gel, and then dry the gel to get magnetic film.52 They 
10 
 
suggested that this biocompatible, magnetic stimuli responsive film might be applied to the 
controlled release of drugs.52 
1.5.4  Poly(oligo (ethylene oxide) monomethyl ether methacrylate) (POEOMA) 
comb-polymer  
As an analog to PEG, OEOMA monomer is biodegradable, biocompatible and 
hydrophilic.53 Furthermore, the methacrylate moiety in OEOMA can undergo controlled radical 
polymerization such as atom transfer radical polymerization method (ATRP) (refer to chapter 
two for details) to get well-defined, narrow distributed POEOMA comb-polymers (Fig. 1.3).54 
 
Figure 1.3. Molecular structure of standard linear PEG and nonlinear POEOMA constructed 
with oligo(ethylene glycol) (macro)monomers.54 
 The obtained POEOMA consists of a carbon-carbon backbone and several oligo(ethylene 
glycol) side chains (Fig 1.3).Owing to the high portion of oligo(ethylene glycol) segments, the 
POEOMA polymer is water-soluble and biocompatible. Also, the maintaining halide end-
functionality in POEOMA enables the consecutive ATRP to get well-controlled copolymers with 
different lengths, types and architectures. For example, by using two consecutive ATRP and post 
modification, our previous group member Dr. Nicky Chan and collaborators designed and 
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synthesized a multidentate block copolymer consisting of one POEOMA hydrophilic block and 
one poly(methacrylic acid) (PMAA) block to bind to the surface of iron oxide nanoparticles.48 
The chain lengths effect of both POEOMA and anchoring block was also explored in their 
following research.55 The experimental results suggest POEOMA based multidentate block 
copolymer with relative long (DP >20) hydrophilic block and anchoring block can stabilize iron 
oxide nanoparticles under biologically relevant conditions and contribute to T1-weighted contrast 
enhancement. 
1.6  Scope of thesis 
This M.Sc research project has focused on developing POEOMA based, catechol 
functionalized mutidentate block copolymer strategy to stabilize iron oxide nanoparticles for 
MRI application. The research is presented in detail in the following three chapters.  
Chapter 2 describes the catechol functionalized multidentate block copolymer (Cat-MDBC) 
stabilized 3.5 nm ultrasmall superparamagnetic Fe3O4 (USNPs) with magnetic resonance 
imaging contrast enhancement and excellent colloidal stability. Several properties of the Cat-
MDBC/USNPs including colloidal stabilities, protein adsorption, relaxivity and in vitro MRI are 
evaluated.  
Chapter 3 describes using similar strategy to stabilize 2 nm extremely small iron oxide 
nanoparticles (ESNPs). These Cat-MDBC/ESNPs are characterized and compared with Cat-
MDBC/USNPs. 




Chapter 2: Mussel-inspired multidentate block copolymer to 
stabilize ultrasmall superparamagnetic Fe3O4 for magnetic 




Colloidal ultrasmall superparamagnetic iron oxide nanoparticles (USNPs) with better 
control of their surface chemistry have been considered as a biocompatible alternative to 
clinically-used gadolinium-based contrast agents for in vivo bright magnetic resonance imaging 
(MRI). Herein, we report a versatile mussel-inspired multidentate block copolymer strategy that 
allows for the stabilization of USNPs as promising MRI contrast agents with excellent colloidal 
stability. Well-controlled multidentate block copolymer with pendant multiple catechol groups 
(Cat-MDBC) is synthesized by a combination of controlled radical polymerization and post-
modification methods. The Cat-MDBC proves to be effective to strongly anchor to USNP 
surfaces as well as provide optimal hydrophilic surfaces; thus, enabling the fabrication of 
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aqueous Cat-MDBC/USNP colloids at single layers with diameter 20 nm through biphasic 
ligand exchange process. They exhibit excellent colloidal stability in broad pH range and 
physiological conditions; no significant protein adsorption; and great magnetic properties 
including relaxivity and in vitro MRI. Further comparison of Cat-MDBC with its corresponding 
catechol-based multidentate random copolymer suggests the importance of the architecture of 
multidentate polymeric ligands for USNP-based MRI diagnosis.  
 
This chapter contains information that was published in Chemistry of 
Materials   2015, 27 (20), 7100–7109 (DOI: 10.1021/acs.chemmater.5b03028) and part of the 




2.1  Introduction   
Magnetic resonance imaging (MRI) is a non-invasive imaging modality exhibiting 
anatomical resolution based on the stimulation of hydrogen protons by means of a precisely 
tuned radio frequency wave. The sensitivity and quality of MRI can be enhanced with the use of 
contrast agents that can induce the change in relaxation time of protons present in their 
immediate vicinity. In particular, colloidal superparamagnetic iron oxide nanoparticles (SNPs) 
are largely considered biocompatible. This is due to biodegradation and metabolism of iron 
oxides into iron ions which can be readily incorporated into the body’s natural iron stores.56-59 
SNPs are generally used as T2-negative contrast agents (dark image). However, the relaxivity of 
SNPs can be varied with their particle sizes and surface chemistry as the magnetic moment of 
SNPs rapidly decreases with decreasing particle size.60-62 As such, ultrasmall SNPs (USNPs) and 
extremely small SNPs (ESNPs) with diameters of <5 nm have been recently explored as a 
biocompatible alternative to gadolinium-based T1-weighted contrast agents (for positive contrast 
enhancement).63-67  
However, a remaining challenge to the biomedical use of SNPs including USNPs and 
ESNPs involves their hydrophobic surfaces that have to be modified to hydrophilic ones; thus 
they can be colloidally stable as well as compatible with biological environments.68, 69 One main 
approach is the ligand exchange process where hydrophobic ligands that originally bound to their 
surfaces such as oleic acids are replaced with hydrophilic ones that possess anchoring groups 
such as carboxylic acids, phosphates, and amines.70, 71 Polymers possessing multiple anchoring 
groups capable of multiple binding interactions with SNP surfaces have been designed as 
effective multidentate ligands.72-74 In particular, multidentate block copolymers (MDBCs) 
consist of one block possessing pendant multidentate anchoring groups strongly bound to SNP 
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surfaces, allowing for the fabrication of aqueous colloidal SNPs with single ligand layers. The 
other hydrophilic block can promote compatibility with biological environments. Recent reports 
have proved that the MDBC stabilization having pendant carboxylates and phosphonates as 
anchoring groups is an effective strategy enabling the fabrication of colloidally-stable SNPs in 
aqueous solutions as effective MRI contrast agents.48, 55, 75-78 Our group has also reported the 
synthesis and conventional ligand exchange of well-controlled MDBCs having pendant 
carboxylic acids in the anchoring block and oligo(ethylene oxide) groups in the hydrophilic 
block (COOH-MDBCs).48 The resultant USNPs stabilized with COOH-MDBCs having longer 
block lengths exhibit enhanced colloidal stability in physiological conditions as well as in vitro 
and in vivo T1-weighted contrast enhancement.
55 However, one concern for carboxylated 
MDBC-coated USNPs involves their negatively-charged surfaces (zeta potential, ζ ≈-10 mV at 
pH = 7). The design of neutral surfaces could be desirable to minimize protein absorption, thus 
providing prolonged blood circulation and enhancing MRI contrast enhancement. 
Inspired by mussels, catechol-based ligands have been utilized as high-affinity anchors.79, 80 
However, most ligands possess one catechol binding units as small molecules, oligomers, or 
macromolecules;81-86 such monodentates impart poor stabilities because of a constant equilibrium 
of adsorption/desorption from the particle surface, eventually causing precipitation due to the 
loss of colloidal stability. Further, catechol-functionalized polymeric multidentates as 
homopolymers,87 random copolymers,88-90 and branched polymers91 have been synthesized. 
However, no reports have described the use of block copolymer-based multidentates having 
pendant multiple catechol groups for the surface modification of SNPs and USNPs yet. 
In this study, we have explored a mussel-inspired multidentate block copolymer strategy to 
stabilize USNPs as an effective T1-positive contrast agent with excellent colloidal stability in 
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various pH and physiological conditions. A combination of controlled radical polymerization, 
hydrolytic cleavage, and facile coupling reaction was employed to synthesize well-defined 
MDBC having pendant catechol groups in the anchoring block and oligo(ethylene oxide) groups 
in the hydrophilic block (Cat-MDBC). Compared with catechol-containing homopolymers, the 
presence of oligo(ethylene oxide) in Cat-MDBCs could provide hydrophilic sheath property 
during blood circulation in vivo, similar to poly(ethylene oxide), an analog of oligo(ethylene 
oxide).92-94 The resultant Cat-MDBC was examined to be effective for a heterogeneous ligand 
exchange process on USNP surfaces, replacing originally-stabilizing monodentates (i.e. oleic 
acid) in an organic layer. This process can allow for fabrication of USNPs stabilized with Cat-
MDBC in aqueous solution, thus forming aqueous Cat-MDBC/USNP colloids with single layers. 
The resulting aqueous Cat-MDBC/USNP colloids were evaluated as effective T1 contrast agents 
for excellent colloidal stability in various pH and physiological conditions, in the presence of 
proteins, and in serum as well as for magnetic properties using relaxometry and in vitro MRI at 
clinical magnetic field strengths. Further, Cat-MDBC was compared with the counterpart of 
multidentate random copolymer having pendant catechol groups (Cat-MDRC) for their 
effectiveness in MRI. 
2.2  Experimental   
2.2.1  Instrumentation and analyses 
1H-NMR spectra were recorded using a 500 MHz Varian spectrometer. CDCl3 singlet at 
7.26 ppm or DMSO-d6 quintet at 2.50 ppm was selected as the reference standard. Monomer 
conversion was determined using 1H-NMR. Molecular weight and molecular weight distribution 
were determined by gel permeation chromatography (GPC) on an Agilent GPC equipped with a 
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1260 Infinity Isocratic Pump and a RI detector was used. Two Agilent PLgel mixed-C and 
mixed-D columns were used with DMF containing 0.1 mol% LiBr at 30 °C at a flow rate of 1.0 
mL/min. Linear poly(methyl methacrylate) standards from Fluka were used for calibration. 
Aliquots of polymer samples were dissolved in DMF. The clear polymer solutions were filtered 
using a 0.2 m PTFE filter to remove any solvent-insoluble species. A drop of anisole was added 
as a flow rate marker.  
Zeta potential () for aqueous Cat-MDBC/USNP colloids and Cat-MDBC at different pH 
values were measured using Zeta Potential Analyzer (Brookhaven) in 10 mM aqueous NaCl 
solution at 25 °C. The pH values were adjusted using 50 mM aqueous HCl and 50 mM aqueous 
NaOH solutions.  
Transmission Electron Microscopy (TEM) images were taken using a Philips Tecnai 12 
TEM, operated at 120 kV and equipped with a thermionic LaB6 filament. An AMT V601 DVC 
camera with point to point resolution and line resolution of 0.34 nm and 0.20 nm respectively 
was used to capture images at 2048 by 2048 pixels. To prepare specimens, USNPs stabilized 
with OAs and Cat-MDBCs in organic and aqueous solutions was dropped onto copper TEM 
grids (400 mesh, carbon coated) and then allowed to air dry at room temperature.  
Dynamic light scattering (DLS) was used to determine hydrodynamic diameters by volume 
of USNPs stabilized with OAs and copolymers in organic and aqueous solutions at a fixed 
scattering angle of 175° at 25 °C with a Malvern Instruments Nano S ZEN1600 equipped with a 
633 nm He-Ne gas laser. 
Thermogravimetric analysis (TGA) measurements were carried out using a TA instruments 
Q50 analyzer. Typically, the dialyzed, freeze dried samples (5-10 mg) were placed into a 
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platinum pan and heated from 25 to 800 °C at a heating rate of 20 °C/min under nitrogen flow. 
The mass loss between 250 and 600 °C was used to calculate the USNP content in Cat-
MDBC/USNPs.   
2.2.2  Materials  
Benzyl alcohol (99%), triethylamine (Et3N, >99.99%), copper(II) bromide 
(CuBr2, >99.99%), tin(II) 2-ethylhexanoate (Sn(EH)2, 95%), trifluoroacetic acid (TFA, 99%), 
iron(II) chloride (FeCl2, 98%), iron(III) chloride (FeCl3, 97%), oleic acid (OA, 97%), dopamine 
hydrochloride, 4-(dimethylamino)pyridine (DMAP, >99.99%), 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC, >98%), immunoglobulin G from human serum (IgG, 
reagent grade, ≥95%, essentially salt-free, lyophilized powder) and  human serum (male, AB 
type)  from Sigma Aldrich as well as Pierce BCA protein assay kit was from Bio-Rad were used 
as received. Oligo(ethylene oxide) methyl ether methacrylate (OEOMA) with MW = 300 g/mol 
and pendant EO#  5 and tert-butyl methacrylate (tBMA) from Aldrich were purified by passing 
through a column filled with basic alumina to remove inhibitors before use. Tris(2-
pyridylmethyl)amine (TPMA),95 benzyl -bromoisobutyrate (Bz-Br),96 and OA-stabilized 
USNPs (OA-USNPs)48 were synthesized as described in our previous publications.  
2.2.3  Synthesis of POEOMA-b-PMAA (COOH-MDBC) 
The detailed synthesis by ATRP is described in appendix A. Molecular weight: Mn = 7,800 





2.2.4  Synthesis of P(OEOMA-co-MAA) random copolymer (COOH-MDRC)  
Similar to COOH-MDBC, two steps were designed. The first step is ATRP of OEOMA and 
tBMA in the presence of Bz-Br with the initial mole ratio of [OEOMA]0/[tBMA]0/[Bz-Br]0 = 
70/70/1.0. Bz-Br (0.1 g, 0.38 mmol), OEOMA (7.9 g, 26.4 mol), tBMA (3.76 g, 26.4 mmol), 
CuBr2 (4.2 mg, 18.7 µmol), TPMA (16.3 mg, 56 µmol), and anisole (24 g) were mixed in a 50 
mL Schlenk flask. The mixture was deoxygenated by purging under nitrogen for 1 hr, and then 
placed in an oil bath at 40 °C. A nitrogen pre-purged solution of Sn(EH)2 (61.2 mg, 151 µmol) 
dissolved in anisole (0.5 g) was injected into the Schlenk flask to initiate polymerization. 
Polymerization was stopped after 3 hrs by cooling the reaction mixture in an ice bath and 
exposing it to air.  
For purification, the as-synthesized polymer solution was precipitated from cold hexane 
three times to remove unreacted monomers. The precipitates were dissolved in acetone and then 
passed through a column filled with basic alumina to remove residual copper species. The 
polymer solution was passed through a 0.2 µm PTFE filter to remove residual tin species. The 
product of P(OEOMA-co-tBMA) was isolated by removal of solvents by rotary evaporation and 
further drying in a vacuum oven at room temperature for 24 hrs. Molecular weight: Mn = 11,900 
g/mol and Mw/Mn = 1.18. 
The next step is the hydrolytic cleavage of P(OEOMA-co-tBMA). The purified, dried 
P(OEOMA-co-tBMA) (0.4 g, 56.5 µmol) dissolved in dichloromethane (8 mL) was mixed with 
TFA (10 fold excess to the mole of pendant t-butoxy groups) under stirring for 24 hrs. The 
resulting mixtures were concentrated using rotary evaporation and precipitated from cold hexane 
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three times. The precipitates were then dried in a vacuum oven at room temperature for 24 hrs to 
form COOH-MDRC.  
2.2.5  Synthesis of Cat-MDBC and Cat-MDRC by coupling reaction 
A EDC coupling reaction was used with the initial mole ratio of 
[COOH]o/[dopamine]o/[EDC]o/[Et3N]o/[DMAP]o = 1/4/1.1/5.5/0.1. Typically, an organic 
solution consisting of the purified, dried COOH-MDBC (0.2 g, COOH = 0.5 mmol calculated 
with the DP of PMAA block), EDC (82 mg, 0.53 mmol), Et3N (54 mg, 0.53 mmol), and DMF (5 
mL) was mixed with an organic solution consisting of Et3N, (215 mg, 2.13 mmol), dopamine 
hydrogen chloride salt (366 mg, 1.93 mmol), DMAP (7 mg, 0.06 mmol), and DMF (5 mL). The 
mixture was stirred at 80 C in an oil bath for 2 days. The solution turned brown. The reaction 
mixture was purified by vacuum filtration, followed by intensive dialysis using a dialysis tubing 
with MWCO = 3.5 kDa over water for 3 days. The purified MDBCs were lyophilized. Similar 
procedure was used for Cat-MDRC. 
2.2.6  Biphasic ligand exchange 
For the preparation of aqueous Cat-MDBC/USNP colloids, aliquots of a stock solution of 
OA-USNPs in hexane (0.4 mg/mL, 5 mL) were mixed with aliquots of aqueous stock solution of 
Cat-MDBC (2 mg/mL, 5 mL). The resulting biphasic mixtures were sonicated using a digital 
sonifier (Branson) for 40 min at 30% amplification. After sonication, the bottom aqueous layer 
was collected, filtered through 0.45 m PES filter, and then purified by an intensive dialysis 
using a tubing with MWCO = 25 kDa over deionized water (2 L) for 3 days. The resulting 
dispersions were lyophilized using a freeze drier. The purified, lyophilized Cat-MDBC/USNPs 
21 
 
could be re-dispersed in water by stirring or sonication. The similar procedure was examined for 
Cat-MDRC and COOH-MDBC.  
2.2.7  Conventional ligand exchange for Cat-MDRC  
Aliquots of the purified, dried Cat-MDRC (10 mg) were mixed with aliquot of the purified 
OA-USNPs (2 mg) in a mixture of 2/1 v/v chloroform/EtOH (5 mL) under magnetic stirring at 
room temperature for 24 hrs. The resulting mixture was precipitated from hexane, and then 
centrifuged at 5,000 rpm for 10 min. The resulting brown pellet was re-dissolved in chloroform 
and the similar procedure was repeated three times to remove unbound OA species. The 
centrifuged pellet was dried in a vacuum oven at room temperature to yield Cat-MDRC/USNPs. 
After ligand exchange, aliquots of Cat-MDRC/USNPs were dispersed in water and dialyzed 
using a dialysis tubing with MWCO = 25 kDa over water (2 L) for 3 days. After dialysis, the 
purified Cat-MDRC/USNPs were lyophilized using a freeze drier. The similar procedure was 
examined for COOH-MDBC.  
2.2.8  Cell viability using MTT assay  
Human embryonic kidney (HEK 293T) and HeLa cancer cells were cultured in DMEM 
(Dulbecco’s modified Eagle’s medium) containing 10% FBS (fetal bovine serum) and 1% 
antibiotics (50 units/mL penicillin and 50 units/mL streptomycin) at 37 C in a humidified 
atmosphere containing 5% CO2. Cells were plated at 5 x 10
5 cells/well into a 96-well plate and 
then incubated with various concentrations of Cat-MDBC/USNP colloids for 48 hrs. Blank 
controls (cells only) were run simultaneously. Cell viability was measured using CellTiter 96 
Non-Radioactive Cell Proliferation Assay kit (MTT, Promega) according to manufacturer’s 
instruction. Briefly, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
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solutions (15 µL) was added into each well. After 4 h incubation, the medium containing 
unreacted MTT was carefully removed. DMSO (100 L) was added into each well in order to 
dissolve the formed formazan blue crystals, and then the absorbance at  = 570 nm was recorded 
using Powerwave HT Microplate Reader (Bio-Tek). Each concentration was 12-replicated. Cell 
viability was calculated as the percent ratio of absorbance of mixtures with colloids to control 
(cells only). 
2.2.9  Colloidal stability in various pH conditions  
Aliquots of aqueous Cat-MDBC/USNP dispersion at 0.2 mg/mL were mixed with the equal 
volumes of buffer solutions at different pHs: an aqueous mixture of 0.1 M NaOH (0.1 mL) and 
0.1 M potassium hydrogen phthalate (50 mL) for pH = 4.0 buffer, a commercially-available PBS 
for pH = 7.4, and an aqueous mixture of 0.1 M NaOH (11 mL) and 0.05 M NaHCO3 (50 mL) for 
pH = 9.8. 
2.2.10 Colloidal stability in human serum  
Aliquots of 150 mM saline aqueous Cat-MDBC/USNP dispersion (5 mg/mL) were mixed 
with different volumes of a human serum to adjust the concentration of Cat-MDBC/USNP to be 
0.4 and 1.7 mg/mL. Colloidal stability was followed by naked eyes over times.   
2.2.11 Colloidal stability in the presence of protein 
Stock solutions of Cat-MDBC/USNPs at 1.2 mg/mL and human IgG at 8 mg/mL were 
prepared in PBS (pH = 7.4). They were mixed and incubated at 37 °C. Aliquots were taken at 48 
and 72 hrs and subjected to centrifugation (18,000 rpm, 4 C, 30 min) in attempt to precipitate 
undesirably-formed aggregates. The concentration of IgG protein in supernatant before and after 
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centrifugation was measured using Pierce BCA protein assay kit at  = 562 nm wavelength and 
compared with that of IgG protein (no Cat-MDBC/USNP) as a control. 
2.2.12 Relaxivity measurements 
Aqueous Cat-MDBC/USNPs dispersion at 1.0 mg/mL was prepared using the similar 
protocol as described above. After aliquots of the dispersion were diluted with different volumes 
of water, the resulting dispersions were dispensed into 7.5 mm o.d. NMR tubes. Their 
longitudinal and transversal relaxation times (T1 and T2) were measured with a dedicated TD-NMR 
relaxometer (Bruker Minispec 60 mq, 60 MHz (1.41 T, 37 °C). For the measurement of T1, a 
standard inversion-recovery sequence was used (180o inversion pulse, followed by a certain 
delay (TI), then a 90o pulse to measure the intensity of the free induction decay signal). After a 
recovery period of at least 3 seconds, the sequence was repeated with a different delay (TI). The 
T1 curve was drawn using points acquired from at least 15 different delays. For T2 measurements, 
a standard Carr-Purcell-Meibom-Gill sequence was used (90o pulse, followed by 180 rephasing 
pulses to induce the echo; the T2 curve was drawn from measurements performed on at least 12 
echos).  The Fe content in the dispersions was precisely determined by Inductively-Coupled Plasma 
Mass spectrometry (ICP-MS; Agilent 7500ce). Prior to ICP measurements, aliquots of each Cat-
MDBC/USNP and Cat-MDRC/USNP dispersion (0.1 mg/mL) were digested overnight at 80 °C 
in HNO3 (trace metal, Fisher Scientific A509–500) and 30% H2O2 (Sigma-Aldrich).  
2.2.13 In vitro MR imaging 
Aliquots of Cat-MDBC/USNP and Cat-MDRC/USNP colloids were dispensed into 500 L 
polyethylene centrifugation tubes. The tubes were immersed in water, inserted in a 60-mm RF 
coil and imaged at 25 C with a 1T small-animal MRI system (M2M, Aspect Imaging, Israel). A 
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T1-weighted 2D spin-echo sequence was used as follows: TE = 10.8 ms; TR = 400 ms; fα = 90°; 
FOV = 70 mm; 1.4 mm slices with 0.1 mm gap; dwell time = 16 s; matrix: 200 × 200; 3 exc. A 
T2-weighted 2D spin-echo sequence was also used: TE = 75 ms; TR = 2500 ms; fα = 90°; FOV = 
70 mm; 1.4 mm slices with 0.1 mm gap; dwell time = 16 s, matrix: 200 × 200; 1 exc. 
2.3  Results and Discussion   
2.3.1  Synthesis of well-defined Cat-MDBC  
As illustrated in Figure 2.1a, well-controlled Cat-MDBC block copolymer (i.e. POEOMA-
b-PMCat) was synthesized by a facile carbodiimide-medicated coupling reaction of pendant 
COOH groups of COOH-MDBC (i.e. POEOMA-b-PMAA) with amino groups of dopamine. As 
described,88 the products were purified by an intensive dialysis to remove byproducts and 
unreacted precursors. 1H-NMR spectroscopy was used to follow the coupling reaction (Figure 
2.1b). 1H-NMR of Cat-MDBC shows the presence of pendant catechol groups at 6.3-6.7 ppm (e), 
pendant OEO moieties at 4.0 ppm (b) and 3.2-3.7 ppm, backbone methyl groups at 0.7-1.1 ppm 
(c, d), and terminal phenyl groups at 7.3 ppm (a). Using the integral ratio of the peaks (b, c, d, 
and e), the extent of coupling reaction was determined to be >90 %. This result suggests the 
successful synthesis of Cat-MDBC having pendant catechol groups.  
The precursor, COOH-MDBC, was synthesized as described in our previous publication.48 
As illustrated in Figure A1 in appendix A, the first step is the consecutive atom transfer radical 
polymerization (ATRP),97, 98 yielding well-controlled POEOMA25-b-PtBMA25 with the degree of 
polymerization (DP) = 25 for both POEOMA and PtBMA blocks. The second step is the 
hydrolytic cleavage of pendant t-butoxy groups of PtBMA block to the corresponding 
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POEOMA-b-PMAA (COOH-MDBC). The detailed synthesis and characterization by 1H-NMR 
for composition and GPC for molecular weight are described in appendix A (Figure A2 and A3).  
 
 
Figure 2.1. Synthesis of Cat-MDBC by a facile coupling reaction of COOH-MDBC with 

























2.3.2  Fabrication and characterization of Cat-MDBC/USNP colloids by 
biphasic ligand exchange 
Colloidal USNPs stabilized with oleic acid (OA-USNPs) was synthesized by co-
precipitation of Fe(II) and Fe(III) in a water/toluene/ethanol mixture. The purified OA-USNPs 
had a diameter = 10 nm in hexane (1 mg/mL) by DLS and core diameter = 3.5 ± 1.1 nm by TEM 
(Figure A4). To fabricate colloidal USNPs stabilized with Cat-MDBC in aqueous solution 
(aqueous Cat-MDBC/USNP colloids), a biphasic ligand exchange method reported in literature99 
was exploited (Figure 2.2a). An aqueous Cat-MDBC solution in water (2 mg/mL) was mixed 
with an organic OA-USNP solution in hexane (0.4 mg/mL) in the equal volumes at the mass 
ratio of Cat-MDBC/OA-USNP = 5/1. The resulting biphasic mixture was then subjected to 
sonication for 40 min and allowed for phase separation at room temperature for 12 hrs. The 
aqueous bottom layer was then carefully decanted and then dialyzed using a dialysis tubing 
(MWCO = 25 kDa) against water in an attempt to remove free (not bound) copolymers, yielding 
a black-colored dispersion at 0.8 mg/mL concentration (III in Figure 2.2a). The resulting 
dispersion was then lyophilized using a freeze-drying method. The dried Cat-MDBC/USNPs 
were readily re-dispersed in aqueous solution by a simple magnetic stirring at various 
concentrations (IV in Figure 2.2a).    
During the ligand exchange process, pendant catechol groups in the copolymer block are 
anchored to USNP surfaces. Such enhanced binding isotherm enables the formation of individual 
USNPs at a single layer of Cat-MDBCs. However, it could also result in the formation of 
undesired large-sized agglomerates or clusters composed of several individual USNPs anchored 
by multiple catechol groups of individual MDBC chains. Considering the core diameter of 
USNPs and the size of Cat-MDBCs in water, the agglomerates could have their diameters greater 
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than approximately 35 nm. Here, DLS result indicates the hydrodynamic diameter of colloidal 
Cat-MDBC/USNP to be 20 nm with monomodal and narrow size distribution in aqueous 
solution (Figure 2.2b). Further DLS analysis suggests the presence of agglomerates (with 
diameter >35 nm) to be <15%. TEM image of Cat-MDBC/USNP colloids shows mostly 
individually-distinct USNPs with a small population of aggregates. Analysis of the TEM image 
gave an average particle core size of 3.4 ± 1.8 nm (Figure 2.2c). These DLS and TEM results 
suggest the formation of a majority of individual Cat-MDBC/USNP colloids due to the 
occurrence of undesired aggregation being minimized through biphasic ligand exchange using 
Cat-MDBC.  
The biphasic ligand exchange process with Cat-MDBC was further evaluated. First, 
inductively-coupled plasma mass spectrometry (ICP-MS) was used to determine Fe content in 
aqueous Cat-MDBC/USNP colloids (2.6 mL) (III in Figure 2.2a). Compared with Fe = 1.1 mg 
used in the recipe, the biphasic ligand exchange efficiency could be calculated to be 9.6 ±1.4% 
(within 14% error with three freshly-prepared dispersions). This means that 9.6% USNPs in 
hexane phase was transferred to aqueous phase (see appendix A for detailed calculation). Next, 
thermogravimetric analysis (TGA) was used to determine the USNP contents in the formed Cat-
MDBC/USNP colloids. As seen in Figure A5, the TGA trace of Cat-MDBC/USNPs shows two 
main weight losses: the initial loss at 0-200 C corresponding to residual water and the other loss 
at 200-450 C to stabilizing ligands (mainly Cat-MDBC). Considering 20% residues at >450 C 
for Cat-MDBC itself, the weight loss at 200-600 C was used to calculate the content of Fe3O4 
USNPs in Cat-MDBC/USNP colloids to be 9.6%, suggesting the actual mass ratio of Cat-
MDBC/USNP = 9.4/1. This value implicates the presence of less USNPs in the colloids, 
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compared with 13.0 % of Fe3O4 USNPs estimated from the recipe based on the mass ratio of 
Cat-MDBC/OA-USNP = 5/1. 
In another set, to examine the effect of the organic solvent on biphasic ligand exchange, the 
similar procedure was repeated with chloroform, instead of hexane as an organic solvent of OA-
USNPs. As seen in Figure A6, the aqueous top layer was not clearly separated from the organic 
chloroform bottom layer after sonication. Further, the DLS diagram of the resultant Cat-
MDBC/USNP colloids shows multimodal distribution. Such unsuccessful ligand exchange in 
chloroform/water system is plausibly due to the greater solubility of POEOMA blocks of Cat-
MDBCs in chloroform than in water, compared with hexane. Hence, Cat-MDBC/USNPs with 
POEOMA coronas could be partitioned in both chloroform and water phases. However, in the 
hexane/water system, Cat-MDBC/USNPs with POEOMA coronas formed during ligand 
exchange could have lower tendency to be partitioned in hexane due to poor solubility of 
POEOMA coronas.  
For comparison, COOH-MDBC (a precursor that was used for the EDC-mediated coupling 
reaction to synthesize Cat-MDBC) was examined for the biphasic ligand exchange method using 
the similar procedure with OA-USNP colloids dissolved in hexane. Different from Cat-MDBC 
(shown in Figure 2.2), the aqueous bottom layer was not clearly separated from the organic 
hexane layer after sonication. Furthermore, the DLS diagram of the resultant COOH-
MDBC/USNP colloids shows multimodal distribution. These results suggest unsuccessful 




Figure 2.2. Schematic illustration of biphasic ligand exchange of OA-USNPs in hexane and cat-
MDBC in water at the mass ratio of Cat-MDBC/USNP = 5/1 wt/wt (a), DLS diagrams (b), and 
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2.3.3  Non-cytotoxicity 
To preliminarily assess aqueous Cat-MDBC/USNP colloids toward MRI applications, in 
vitro cytotoxicity with both HEC 293T normal and HeLa cancer cells were examined using MTT 
assay (a calorimetric method to measure cell toxicity). Aliquots of different concentrations of 
aqueous Cat-MDBC/USNP colloids were cultured with cells. Cells only were also included as 
controls. After 48 hr incubation, the absorbance was measured using absorbance-based plate 
reader and used to calculate cell viability. Figure 2.3 suggests >80% viability of both cells in the 
presence of aqueous Cat-MDBC/USNP colloids, suggesting non-cytotoxicity of aqueous Cat-
MDBC/USNP colloids up to 200 g/mL. 
 
Figure 2.3. Viability of HEK 293T and HeLa cells cultured with various concentrations of 



























2.3.4  Excellent colloidal stability in various pH and physiological conditions  
Excellent colloidal stability with no occurrence of large aggregation in biological conditions 
is critical to achieve prolonged blood retention time and optimal relaxometric properties for MRI 
since they are strongly affected by the size and surface charge of nanoparticles in vivo. Thus, zeta 
potential () of aqueous Cat-USNP/MDBC colloids was measured in 10 mM saline solution over 
pH. As seen in Figure 2.4a, the  of aqueous Cat-MDBC/USNP colloids is close to zero in a 
broad range of pH at 3-9, suggesting the surface of Cat-MDBC/USNP colloids presents to be 
neutral in physiological pH = 7.0-7.5. This result is greatly advantageous to endow prolonged 
colloidal stability in physiological conditions as well as minimize non-specific interactions with 
proteins in blood.100 Additionally, the  of Cat-MDBC/USNP colloids is greater than that of Cat-
MDBC itself which ranges at -15 - -30 mV at pH >7. Such difference of the  between Cat-
MDBC/USNP colloids and Cat-MDBC could suggest that most catechol groups are bound to 
USNP surfaces in aqueous Cat-MDBC/USNP colloids.  
To examine excellent colloidal stability, aliquots of aqueous Cat-MDBC/USNP colloids 
were incubated at different pHs. As seen in Figure 2.4b, their diameter kept unchanged in the 
broad range of pH = 4, 7, and 9 at 37 C, suggesting no significant effect of pH on colloidal 
stability of neutral Cat-MDBC/USNP colloids. Next, aqueous Cat-MDBC/USNP colloids were 
then incubated with human serum in a physiological condition (pH = 7.3 at 37 C). Figure 2.4c 
shows no occurrence of significant precipitation of Cat-MDBC/USNP colloids at both 0.4 and 
1.7 mg/mL concentrations over 96 hrs. Further, aqueous Cat-MDBC/USNP colloids (1.2 mg) 
were incubated with human IgG protein (8 mg/mL) in a physiological condition (pH = 7.3 at 37 
C). IgG is found at 7-16 mg/mL in human blood stream. Even though the size and size 
distribution of Cat-MDBC/USNP colloids were similar to those of IgG proteins, DLS results 
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show no evidence of aggregation (Figure A8). Further to quantify the interaction of Cat-
MDBC/USNPs with IgG, bicinchoninic acid (BCA) assay was used.101 As seen in Figure 2.4d, 
aqueous Cat-MDBC/USNP colloids exhibit no significant specific interactions with human IgG. 
These results suggest that Cat-MDBC/USNP colloids are colloidally stable in the presence of 
proteins and do not exhibit significant protein absorption.  
We now would like to provide the comparison of colloidal stability of Cat-MDBC/USNP 
colloids with COOH-MDBC/USNP colloids (Figure A9). Note that aqueous COOH-
MDBC/USNP colloids with diameter 16 nm by DLS were prepared using conventional ligand 
exchange process (see appendix A), while aqueous Cat-MDBC/USNP colloids were prepared by 
biphasic ligand exchange. Similar to Cat-MDBC/USNP colloids, the formed COOH-
MDBC/USNP colloids exhibit excellent colloidal stability in the presence of IgG protein (8 
mg/mL) and in serum at pH = 7, although they had the   -10 mV at the pH. They were also 
colloidally-stable in a broad range of pH = 4-10. Given these promising results, animal studies 
should be conducted to better understand in vivo colloidal stability of both Cat-MDBC/USNP 




Figure 2.4. For aqueous Cat-MDBC/USNP colloids, evolution of their zeta potential over pH 
compared with Cat-MDBC (a), evolution of their diameter over time at various pH = 4, 7, and 10 
(b), digital images of their mixtures with human serum at 0.4 and 1.7 mg/mL (c), and no 
significant interaction with IgG protein (8 mg/mL) over 72 hrs determined BCA assay (d). Inset 
in (d) shows the digital picture of their mixtures with IgG proteins after 72 hr incubation. 
 
2.3.5  Relaxometric analysis and in vitro T1-weighted MRI.  
To preliminarily evaluate aqueous Cat-MDBC/USNP colloids with excellent colloidal 
stability as an effective T1 contrast agent, their relaxometric properties were determined at 
clinical magnetic field strengths (1.41 T, corresponding to 60 MHz). Longitudinal and transverse 
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magnetic relaxation times (T1 and T2 respectively) were measured on dilutions of the colloids 
(Figure 2.5). From the slopes, the relaxivity was determined to be r1 = 6.8 mM
-1s-1 and r2/r1 = 5.5. 
These values are close to those expected for individual USNPs; for example, r1 = 10.7 mM
-1s-1 
and r2/r1 = 3.6 for commercially-available Supravist (SHU-555C)
102 and r1 = 4.5-4.8 mM
-1s-1 and 
r2/r1 = 3.4 – 6.1 for PEGylated USNPs.48, 64, 67 In addition, from the intercepts, 1/T1 = 0.31 s-1 and 
1/T2 = 0.88 s
-1 were estimated at [Fe] = zero (meaning no presence of Cat-MDBC/USNP colloids; 
i.e. pure water). These values are similar to the reported 1/T1 = 0.24 ± 0.03 s
-1 and 1/T2 = 0.8 ± 
0.1 s-1 for pure water determined at 1.5 T.103 This comparison validates the reliability of our 
determination of the relaxivity data. Further, in vitro T1-weighted MRI of aqueous Cat-
MDBC/USNP colloids was conducted at clinical magnetic field strength (1.41 T). Their 
favorable relaxometric properties provide brighter T1-weighted imaging at as low as 0.38-0.57 
mM Fe concentration. Promisingly, this concentration is significantly lower than that (0.9-1.9 
mM Fe) for the corresponding COOH-MDBC having pendant carboxylates.55 These results are 
promising in that Cat-MDBC/USNP colloids hold a great potential as an effective T1 contrast 





Figure 2.5. Relaxation rates (1/T1 and 1/T2) and T1-weighted MRI for aqueous Cat-
MDBC/USNP colloids at 1.41 T at 37 C. 
 
2.3.6  Multidentate: block vs. random copolymer (Cat-MDBC vs. Cat-MDRC)  
The above results indicate that Cat-MDBC (block copolymer) enables the formation of 
aqueous single-layered Cat-MDBC/USNPs colloids with diameter 20 nm as an effective T1 
contrast enhancement agent for MRI. Here, we compare Cat-MDBC with the corresponding 
multidentate random copolymer (Cat-MDRC). Note that the density of pendant catechol 
groups in Cat-MDRC was designed to be similar to Cat-MDBC (Figure 2.6a). 
Figure A10a illustrates our synthetic scheme of Cat-MDRC. First, COOH-MDRC was 
synthesized by two steps: 1) ATRP of OEOMA and tBMA to yield well-controlled random 
P(OEOMA-co-tBMA) with DP = 25 for OEOMA units and DP = 31 for tBMA units and 2) 
hydrolytic cleavage of pendant t-butoxy groups of tBMA  units to the corresponding P(OEOMA-

























r1 = 6.8 mM
-1s-1




co-MAA) (i.e. COOH-MDRC). Next, similar to Cat-MDBC, well-controlled Cat-MDRC was 
synthesized by the carbodiimide-medicated coupling reaction of pendant COOH groups of 
COOH-MDRC with amino groups of dopamine. 1H-NMR of the resultant Cat-MDRC shows the 
presence of pendant catechol groups at 6.3-6.7 ppm (e), pendant OEO moieties at 4.0 ppm (b) 
and 3.2-3.7 ppm, backbone methyl groups at 0.7-1.1 ppm (c, d), and terminal phenyl groups at 
7.3 ppm (a). Similar to Cat-MDBC, the integral ratio of the peaks (b, c, d, and e) was used to 
determine the extent of coupling reaction to be >90% (Figure A10b). 
After the successful synthesis of Cat-MDRC, the similar procedure for biphasic ligand 
exchange was examined in aqueous solution at the mass ratio of Cat-MDRC/USNP = 5/1 wt/wt. 
Both DLS and TEM results suggest the formation of multimodal clusters of Cat-MDRC/USNP 
colloids with their average diameters to be 40 and 115 nm (Figure 2.6b and 2.6c). Further to see 
if the formation of large clusters is due to biphasic ligand exchange process, the conventional 
ligand exchange process was examined, where OA surface ligands were replaced with new Cat-
MDRC ligands on USNPs in organic solution (chloroform/EtOH solvent mixture). The resulting 
Cat-MDBC/USNP colloids were dispersed in water, yielding clusters with the diameter to be 
42.6 nm and large aggregates (diameter >1 m) in aqueous solution (Figure A11 of DLS 
diagram). These results are different from the formation of single layered Cat-MDBC/USNP 
colloids; the plausible reason could be the random distribution of pendant catechol groups, 
compared to their spatial localization as a block. 
Further, the cluster-like colloids presented transverse relaxivity constant r2 = 93.5 mM
-1s-1, 
which is close to typical values of negative MRI contrast agents of clusters having SNPs with 
diameter  4 nm104 (Figure 2.6d and 2.6e). This result suggests that Cat-MDRC forms aggregate-
37 
 




Figure 2.6. For Cat-MDRC, chemical structure (a), DLS diagram (b), TEM image (c), relaxation 
rates (1/T1 and 1/T2) (d), and in vitro MRI at 1.41T at 37 C (e). 
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2.4  Conclusion   
Well-controlled Cat-MDBC having pendant catechol groups in the anchoring block strongly 
bound to USNP surfaces was synthesized by consecutive ATRP followed by post-modification 
methods. The Cat-MDBC was proved to be an effective multidentate that enabled the 
replacement of originally-stabilizing monodentates (oleic acids) on USNP surfaces, allowing for 
the fabrication of aqueous Cat-MDBC/USNP colloids with diameter <20 nm through the 
biphasic ligand exchange process. The resulting colloids are non-toxic to cells up to 200 g/mL. 
They exhibit excellent colloidal stability in a broad range of pH = 4-10 as well as in the presence 
of IgG model protein and even in human serum, plausibly due to the nature of pendant catechol 
groups being neutral in charges, combined with the presence of pendant oligo(ethylene glycol)-
containing polymethacrylate providing excellent hydrophilic sheaths. Different from Cat-MDBC, 
Cat-MDRC (the counterpart of Cat-MDBC) formed undesired clusters of USNP colloids as 
aggregates, not single layered Cat-MDRC/USNP colloids, by both biphasic and conventional 
ligand exchange. These results, combined with the relaxivitiy and in vitro MRI results, suggest 
that aqueous Cat-MDBC/USNP colloids hold a great potential as an effective contrast agents for 




Chapter 3: Extremely small-sized Fe3O4 nanoparticles as MRI 
contrast agents 
3.1  Introduction   
In chapter 2, I demonstrate that mussel-inspired multidentate block copolymer strategy is an 
effective and versatile method to stabilize USNPs with the diameter ≈3 nm. The aqueous Cat-
MDBC/USNP colloids fabricated by biphasic ligand exchange process exhibit excellent colloidal 
stability in physiological conditions, in the presence of protein, and in human serum. They have 
higher r1 value (6.8 mM
-1s-1) and relatively lower r2/r1 value (5.5), suggesting effective T1-
contrast agents. To be comparable with Gd3+-based T1-contrast agents with r2/r1 <2, the magnetic 
properties of Fe3O4 nanoparticles should be further improved. A recent report describes that 
extremely small Fe3O4 nanoparticles (ESNPs) with diameter <3 nm can be applicable because 
they have smaller magnetic moment and can improve the image quality of T1-weighted MRI. 
9, 
105. Inspired by these reports of ESNP colloids, this chapter describes our preliminary results 
from my efforts to exploit our mussel-inspired Cat-MDBC strategies towards ESNPs with 
diameter <2 nm as effective bright T1-contrast agents. After the surface functionalization with 
Cat-MDBC, the Cat-MDBC/ESNPs were further characterized and compared with Cat-MDBC 
/USNPs with 3.5 nm core.  
3.2  Experimental   
The detailed experimental procedures and conditions including material, instruments and 
analysis of NMR, TGA, biphasic ligand exchange, colloidal stability in the presence of IgG, cell 




3.2.1  Synthesis of oleic acid stabilized ESNPs (OA-ESNPs)  
The OA-stabilized ESNPs were synthesized follow the procedures described in 
publication.105, 106 For the synthesis of iron-oleate complex precusor, FeCl3 (0.65 g 4 mmol) was 
mixed with sodium oleate (3.65 g, 12 mmol)  in 4/3/7 v/v/v  EtOH/H2O/hexane mixture (28 mL). 
The mixture was heated at 70oC for 4 hrs and cooled to room temperature. The upper organic 
layer was separated and washed with water (10 mL) three times. Solvents were removed by a 
rotary evaporation and residues were dried in a vacuum oven at room temperature for 24 hrs.  In 
the next step, the synthesized iron-oleate complex (1.8 g) was mixed with oleyl alcohol (3.22 g, 
12 mmol) in diphenyl ether (10g). After being degased at 90 oC under vacuum for 2 hrs, the 
mixture was heated to 200 oC at 10 oC/min and kept at the same temperature for 30 mins under 
N2 atmosphere. The whole system was rapidly cooled to room temperature and then precipitated 
from acetone.  The products were dried in a vacuum oven at room temperature for 24 hrs, 
yielding OA-ESNPs brown, sticky solids.  
3.2.2  Synthesis of Cat-MDBC 
Well-controlled Cat-MDBC was synthesized by a combination of ATRP and post-
modificaiton methods as described in chapter 2. The precursor POEOMA-b-PtBMA synthesized 




3.2.3  UV-Vis spectroscopic titration  
UV-Vis titrations were performed using a UV/Vis/NIR spectrometer (B&W Tek i-Trometer) 
equipped with BDS130 UV/Vis/NIR light source. All titrations were conducted under magnetic 
stirring in quartz cuvette at room temperature. First, blanked the UV machine using 2.5 mL pH 7 
Tris-HCl buffer. Prepared aqueous Cat-MDBC (MW = 13500 g/mol) in Tris-HCl buffer of pH = 
7 at 2.6 mg/mL concentration. An aliquot of the polymer solution (0.2 mL, 0.038 µmol Cat-
MDBC) was mixed with  Tris-HCl buffer (2.5 mL). Measured the UV-visible absorption of the 
resulting mixture before titration. Titration of this stock solution was conducted using FeCl3 
aqueous solution at 1.3 mg/mL under magnetic stirring. Each time 25 µL FeCl3 (0.2 µmol) 
aqueous solution was added to Cat-MDBC stock solution and was stirred for 2 mins before UV-
visible absorption measurement. UV-Vis titration experiments were performed in duplicate for 
Cat-MDBC. Similarly, UV-Vis titration of dopamine hydrochloride using FeCl3 was performed. 
Prepared dopamine hydrochloride (MW = 189.6 g/mol) in Tris-HCl buffer of pH = 7 at 0.95 
mg/mL concentration. An aliquot of the dopamine hydrochloride solution (0.2 mL, 1 µmol 
dopamine hydrochloride) was mixed with Tris-HCl buffer (2.5 mL). Measured the UV-visible 
absorption of the resulting mixture before titration. Titration of this stock solution was conducted 
using 1.3 mg/mL FeCl3 water solution following same process as Cat-MDBC titration. 
Following the similar process, 0.2 mL 2.97 mg/mL Cat-MDBC/ESNPs in Tris-HCl buffer of pH 
= 7 (containing Cat-MDBC 0.038 µmol) was mixed with Tris-HCl buffer (2.5 mL) and titrated 




3.2.4  Colloidal stability in physiological conditions  
For colloidal stability in physiological conditions, Cat-MDBC/ESNPs were directly 
dispersed in PBS at 0.5 mg/mL. The colloidal was incubated at 37 oC over five days.  
3.3  Results and Discussion   
Well-defined OA-ESNPs was synthesized using heat-up method as reported in literature.105 
The resulting OA-ESNPs have their diameter = 5.7 ± 0.2 nm dispersed in hexane by DLS (Figure 
3.1b) and the core diameter = 2.1 ± 0.4 nm by TEM. Note that the particle morphologies are not 






Figure 3.1. TEM image of OA-ESNPs (a), and Cat-MDBC/ESNP colloids (c). DLS diagrams of 
OA-ESNPs in hexane at 0.5 mg/mL and Cat-MDBC/ESNPs in water at 0.5 mg/mL (b). 
 
For the fabrication of ESNPs stabilized with Cat-MDBC in aqueous solution (aqueous Cat-
MDBC/ESNP colloids), our biphasic ligand exchange process was examined. As reported, a 
biphasic mixture of aqueous solution of Cat-MDBC and organic solution of OA-ESNPs in 
hexane was subjected to sonication at room temperature. The aqueous layer carefully taken was 
subjected to intensive dialysis over distilled water and then lyophilized using freeze-drier. The 
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dried Cat-MDBC/ESNPs colloids were readily re-dispersed in aqueous solution at various 
concentrations.  The Cat-MDBC/ESNPs have hydrodynamic diameter to be ≈13.8 nm by DLS 
(Figure 3.1b) and TEM results indicate the core diameter of ESNPs in individual Cat-
MDBC/ESNPs colloids to be 1.9 ± 0.6 nm(Figure 3.1c). The dried Cat-MDBC/ESNPs were 
analyzed through thermogravimetric analysis (TGA) to determine the content of ESNPs in the 
dried colloids (Figure B1 in appendix B). The ESNPs content in Cat-MDBC/ESNPs was 
calculated to be 14.1%.  
 
Figure 3.2. Biphasic ligand exchange of OA-ESNPs in hexane and cat-MDBC in water at the 
mass ratio of Cat-MDBC/ESNP = 5/1 wt/wt. 
 
Further, we have attempted to determine the percentage of free catechol groups not bound 
to ESNPs surface using UV-Vis spectroscopic titration. This method follows UV-Vis absorbance 
at 570 nm as a result of the formation of complex between catechol groups and Fe3+ ions in 
aqueous solution in pH 7.107, 108 First, UV-Vis titration of dopamine hydrochloride in pH = 7 
Tris-HCl buffer reveals the equivalent of Fe3+: catechol = 1:1, which indicates the 1:1 ratio of 
Fe3+: catechol in complex (appendix B, Figure B2). The molar absorptivities of Fe3+-catechol 
complex at different wavelength were also obtained (appendix B, Figure B3). The UV-Vis 
titration spectral changes of Cat-MDBC using Fe3+ at same condition are quite similar to that of 












formation of complex (λmax = 570 nm), the UV-Vis spectra first show increasing absorbance at 
570 nm then reach the plateau corresponding to the saturation of all the catechol groups in the 
polymer by Fe3+. Since Cat-MDBCs exhibit no absorbance at 570 nm, the increasing absorbance 
at 570 nm from beginning point to the plateau (0.28 ± 0.01) is proportion to the concentration of 
Fe(III)-catechol complex as well as the initial concentration of catechol groups. We further 
conducted UV-Vis titration of Cat-MDBC/ESNPs having same amount of Cat-MDBC (using the 
Cat-MDBC% information from TGA), the absorbance at 570 nm before addition of Fe3+ iron 
corresponds to the binding of catechol with the surface of ESNPs. The increasing absorbance at 
570 nm from beginning point to the plateau (0.14 ± 0.01) is proportion to the concentration of 
Fe(III)-catechol complex formed by Fe3+ irons in titrating solution and catechol groups which 
were not bound to the surface of ESNPs. Through calculation (refer to appendix B for details), 




Figure 3.3. UV−Vis spectroscopic monitoring during titration of Cat-MDBC (a1), Cat-
MDBC/ESNPs (b1). Profiles of the absorbance at 570 nm with the addition of the Fe3+ into Cat-
MDBC (a2), Cat-MDBC/ESNPs (b2). 
 
Next, the formed Cat-MDBC/ESNP colloids were preliminarily assessed toward MRI 
applications. Firstly, in vitro cytotoxicity with both HEC 293T normal and HeLa cancer cells 
were examined using MTT assay. As seen in Figure 3.4, the viability of both cells was >80%  in 
the presence of aqueous Cat-MDBC/ESNP colloids, suggesting non-cytotoxicity of aqueous Cat-
MDBC/USNP colloids up to 200 g/mL, similar to Cat-MDBC/USNP colloids 













































































Secondly, colloidal stabilities of the Cat-MDBC/ESNPs were examined in physiological 
condition (in PBS buffer at pH = 7.4) and in the presence of IgG protein at 37 oC. As seen in 
Figure 3.4a, the diameter of Cat-MDBC/ESNP colloids remained stable in PBS solution at 37 C. 
Then, aqueous Cat-MDBC/ESNP colloids (1.2 mg) were incubated with human IgG protein (8 
mg/mL) in a physiological condition (pH = 7.3 at 37 C). Their size and size distribution kept 
unchanged by DLS (Figure 3.4b) and no occurrence of significant interactions with human IgG 
was observed by BCA assay (Figure 3.4d). These results suggest that Cat-MDBC/ESNP colloids 
are colloidally stable in the presence of proteins and prevents from protein adsorption in 






Figure 3.4. For aqueous Cat-MDBC/ESNP colloids evolution of their diameter over time in PBS 
at 37 oC (a), and DLS traces of Cat-MDBC/ESNPs and IgG incubated for 18 hrs and 24 hrs at 37 
oC (b), Viability of HEK 293T and HeLa cells cultured with various concentrations of aqueous 
Cat-MDBC/ESNP colloids at 37 C for 48 hrs, determined by MTT assay (c) and interaction of 
Cat-MDBC/ESNPs with IgG proteins over 24 hrs determined BCA assay (d). 
 
Thirdly, the colloidally-stable aqueous Cat-MDBC/ESNPs as an effective T1 contrast agent 
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corresponding to 60 MHz). Longitudinal and transverse magnetic relaxation times measurements 
(T1 and T2 respectively) were performed on dilutions of the colloids (Figure 3.5). From the slopes, 
the relaxivity parameters were determined to be r1 = 3.0 mM
-1s-1 and r2/r1 = 1.5. As compared in 
relaxivity parameters in Table 3.1, the r2/r1 value of Cat-MDBC/ESNPs is significantly lower 
than Cat-MDBC/USNPs and Supravist with their core diameter >3 nm and promisingly are 
comparable with that r2/r1 = 1.4 of Gd
3+-based T1-contrast agents (PEG-Gd2O3). T1 signal 
enhancement (bright image) was observed at low concentration of Fe of 0.22 ~ 0.32 mM. These 
results, together with the r1 and r2 values mentioned above, suggest that Cat-MDBC/ESNPs can 
be promising candidate as T1-weighted MRI contrast agents and competitive alternative for 
Gadolinium-based contrast agents.  
 
Table 3.1. Size and relaxivity parameters (r2, r2/r1) of various contrast agents measured at 1.4 T 
 Core  DTEM (nm) r2 (mM


















































Figure 3.5. Relaxation rates (1/T1 and 1/T2) and T1-weighted MRI for aqueous Cat-
MDBC/ESNP colloids at 1.41 T at 37 C. 
 
3.4  Conclusion   
ESNPs with core diameter <2 nm were successfully synthesized and coated with Cat-
MDBCs. The resulting Cat-MDBC/ESNPs colloids with diameter <17 nm exhibit excellent 
colloidal stability in physiological conditions (PBS, 37 oC) and in the presence of IgG, owing to 
hydrophilic sheath from POEOMA block. The in vitro MRI and relaxivity results suggest that 
decrease in size of iron oxide nanoparticle dramatically decreases the T2 effect of Cat-





























0.32 mM Fe 0.22 mM Fe H2O
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MDBC/ESNPs, thus providing great potential of Cat-MDBC/ESNPs as a promising 
biocompatible alternative to Gd3+-based T1-weighted MRI contrast agents. 
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Chapter 4: Conclusion and Future work 
A combination of ATRP and post-modification methods were utilized to synthesize well-
controlled catechol functionalized block copolymers (Cat-MDBCs) having pendant catechol 
groups in anchoring block and pendant oligo (ethylene glycol) in the hydrophilic block. They 
were revealed to be effective multidentate ligands to stabilize USNPs with core diameter = 3.5 
nm and ESNPs with core diameter = 2 nm in physiological conditions. The new Cat-
MDBC/USNPs and ESNPs colloids were proved to be valuable as T1-MRI contrast agents. The 
influence of ligand exchange method (biphasic vs. homogenous), architectures of stabilizers 
(random copolymer Cat-MDRC vs. block copolymer Cat-MDBC) and different types of 
anchoring groups (carboxylate vs. catechol) on the properties of copolymer-USNPs complex 
were explored in detail in Chapter 2. The Cat-MDBC/USNPs colloids (hydrodynamic diameter 
<20 nm) obtained by biphasic ligand exchange exhibit excellent colloidal stability as well as 
promising relaxivity properties and effective T1-MRI signal enhancement. The influences of the 
core size of iron oxide nanoparticle on relaxivity properties are discussed in chapter 3. After 
decreasing the size of SNPs from 3.5 nm (USNPs) to 2 nm (ESNPs), the Cat-MDBC/ESNPs 
fabricated by biphasic ligand exchange exhibit less T2 effect and comparable relaxivity property 
with Gd3+-based T1-contrast agents. The current design of the Cat-MDBC and the biphasic ligand 
exchange process can be improved in the future. For example, the density of unbound catechol 
groups in Cat-MDBC/ESNP colloids might be reduced by optimizing the catechol groups in Cat-
MDBC. Further, a considerable effort should be made to improve the efficiency of biphasic 
ligand exchange. In addition, the in vivo experiments should be conducted to further evaluate the 
properties of Cat-MDBC/USNPs and Cat-MDBC/ESNPs as the MRI contrast agents, such as 
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I) Synthesis and characterization of COOH-MDBC 
Figure A1. Synthetic route to COOH-MDBC by consecutive ATRP and hydrolytic cleavage. 
 
Synthesis of POEOMA-Br macroinitiators. Bz-Br (0.19 g, 0.75 mmol), OEOMA (16.9 g, 
0.06 mol), CuBr2 (11.2 mg, 50 µmol), TPMA (43.6 mg, 0.15 mmol), and anisole (16.1 g) were 
mixed in a 50 mL Schlenk flask. The mixture was deoxygenated by purging under nitrogen for 1 
hr and then placed in an oil bath at 30 °C. A nitrogen pre-purged solution of Sn(EH)2 (28.5 mg, 
70.3 µmol) dissolved in anisole (0.75 g) was injected into the Schlenk flask to initiate 
polymerization. Polymerization was stopped after 1 hr by cooling the reaction mixture in an ice 
bath and exposing it to air.  
For purification, the as-synthesized polymer solution was precipitated from cold hexane 
three times to remove unreacted monomers. The precipitates were dissolved in acetone and then 
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passed through a column filled with basic alumina three times to remove residual copper species. 
The polymer solution was passed through a 0.2 µm PTFE filter to remove residual tin species. 
Solvents were removed by rotary evaporation and the residues were dried in a vacuum oven at 
room temperature for 24 hrs, yielding well-controlled POEOMA-Br macroinitiators (MI) having 
Mn = 7,800 g/mol and Mw/Mn = 1.24.  
Synthesis of POEOMA-b-PtBMA. POEOMA-Br (1.3 g, 0.16 mmol), tBMA (1.8 g, 12.8 
mmol), CuBr2 (1.8 mg, 8.0 µmol), TPMA (7 mg, 24 mol), and anisole (6.75 g) were mixed in a 
25 mL Schlenk flask. The mixture was deoxygenated by purging under nitrogen for 1 hr, and 
then placed in an oil bath at 40 °C. A nitrogen pre-purged solution of Sn(EH)2 (25.8 mg, 63.8 
µmol) dissolved in anisole (0.5 g) was injected into the Schlenk tube to initiate polymerization. 
Polymerization was stopped after 3 hr by cooling the reaction mixture in an ice bath and 
exposing it to air. Similar procedure to purify the resulting block copolymers was used as 
described above to yield POEOMA-b-PtBMA having Mn = 9,300 g/mol and Mw/Mn = 1.24.  
Hydrolytic cleavage to synthesize POEOMA-b-PMAA (COOH-MDBC). The purified, 
dried POEOMA-b-PtBMA (0.4 g, 56.5 µmol) dissolved in dichloromethane (DCM, 8 mL) was 
mixed with 10 fold excess of TFA under stirring for 24 hrs. The resulting mixtures were 
concentrated using rotary evaporation and precipitated from cold hexane three times. The 
precipitates were then dried in a vacuum oven at room temperature for 24 hrs. After cleavage, the 





Figure A2. 1H-NMR spectra of POEOMA-Br (a), POEOMA-b-PtBMA (b) in CDCl3, and 
POEOMA-b-PMAA in DMSO-d6 (c). 
 
The degree of polymerization (DP) was determined from the integral ratio of peaks 
































Figure A3. GPC traces of POEOMA-Br and POEOMA-b-PtBMA. 
 
 
II) Biphasic ligand exchange 










Mn = 7,800 g/mol
Mw/Mn = 1.24
POEOMA-b-PtBMA-Br




Calculation of biphasic ligand exchange efficiency by ICP measurements: 
From ICP measurements, Fe = 37.8 ppm in 2.6 mL recovered water phase after biphasic 
ligand exchange. Thus, Fe = 0.098 mg. From the recipe, OA-USNPs = 2 mg; Fe3O4 content in 
OA-Fe3O4 = 75% by TGA and Fe content in Fe3O4 = 72.4% by elemental calculation. Thus, Fe = 
2 mg × 0.75 × 0.724 = 1.09 mg (assuming that all Fe3O4 NPs in hexane are transferred to 
aqueous phase during biphasic ligand exchange process) Thus, efficiency = 0.098 mg/1.09 mg × 
100 = 9%. 



























Figure A6. DLS diagram and digital image (inset) of Cat-MDBC/USNP colloids in water, 


































Figure A7. DLS diagram and digital image (inset) of COOH-MDBC/USNP colloids in water, 
prepared by biphasic ligand exchange process with hexane as an organic phase. 
  

































III) Colloidal stability 
Figure A8. DLS diagrams of aqueous Cat-MDBC/USNP colloids incubated with IgG protein (8 
mg/mL) for 48 and 72 hrs. 
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 IgG in PBS 8 mg/mL
 CatMDBC/USNPs + IgG, t = 0
 CatMDBC/USNPs + IgG, t = 48 hrs


















IV) Colloidal stability of COOH-MDBC/USNPs 
Figure A9. For aqueous COOH-MDBC/USNP colloids prepared by conventional ligand 
exchange process, DLS diagram in aqueous solution (a), no significant interaction with IgG 
protein (8 mg/mL) over 72 hrs determined by BCA assay (b), digital images of their mixtures 
with human serum at 0.4 and 1.7 mg/mL (c), and evolution of their diameter over time at various 
pH = 4, 7, and 10 (d). 
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V) Synthesis and ligand exchange of Cat-MDRC 


















Figure A11. DLS diagram of Cat-MDRC/USNP colloids in water, prepared by conventional 





























I) Biphasic ligand exchange 
Calculation of biphasic ligand exchange efficiency by ICP measurements 
From ICP measurements, Fe = 18.4 ppm in 8.1 mL recovered water phase after biphasic 
ligand exchange. Thus, Fe = 0.149 mg. From the recipe, OA-ESNPs = 7.5 mg; Fe3O4 content in 
OA-ESNPs = 45.5% by TGA and Fe content in Fe3O4 = 72.4% by elemental calculation. Thus, 
Fe = 7.5 mg × 45.5% × 72.5% = 2.47 mg (assuming that all Fe3O4 NPs in hexane are transferred 
to aqueous phase during biphasic ligand exchange process). Thus, efficiency = 0.149 mg/2.47 
mg × 100 = 6%. 
























Table B1. Weight lose calculation based on TGA results 
TGA A B C D E 
 Point 1 around 















without H2O and 
if all polymer 
burnt out 
D/88.1% 
Cat-MDBC 96.3% 11.5% 84.8 88.1  
OA-ESNPs 89.6% 40.8% 48.8 54.5  





II) Calculation of UV-Vis titration  
Figure B2. UV−Vis spectroscopic monitoring during titration of dopamine hydrocholoride using 
Fe3+ (a), Profiles of the absorbance at 570 nm with the addition of the Fe3+ into dopamine 
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Figure B3. The molar absorptivities (ε in Beer-Lambert Law A =εcl) of Fe3+, dopamineHCl their 
complex at different wavelength. 
 
Calculation of percentage of unbound catechol groups based on UV-Vis titration: 
Figure B4. UV−Vis spectra overlap of the Cat-MDBC and Cat-MDBC/ESNPs before and after 
titration (left).Overlap of the absorbances at 570 nm with the addition of the Fe3+ into Cat-
MDBC and Cat-MDBC/ESNPs (right).  
 








































The first calculation method is based on the changes in Abs at 570 nm from starting point to 
the plateau during the titration (ΔACat-MDBC, ΔACat-MDBC/ESNPs shown in Figure B4) as well as the 
linear fitting Abs = Slope × Mole Fe + intercept obtained from the data point of Cat-MDBC 
titration before reaching the plateau. The linear fitting obtained from trial 1 and trial 2 were Abs 
= 0.448 Mole Fe + 0.015 and Abs = 0.374 Mole Fe + 0.026 respectively. ΔACat-MDBC = 0.28 ± 0.01, 
so according to the linear fitting the corresponding ΔMole Fe = 0.625 mol and 0.748 mol 
respectively and the average is 0.687 mol. Similarly, ΔACat-MDBC/ESNPs = 0.14 ± 0.01 
correspondingto ΔMole Fe = 0.313 mol and 0.374 mol respectively and the average is 0.344 mol. 
Since under these titration condition, the equivalent of Fe3+: catechol = 1:1, and the total amount 
of Cat-MDBC is designed to be same in UV-Vis titration of Cat-MDBCs and Cat-MDBC/ESNPs 
so the percentage of unbound catechol groups in Cat-MDBC/ESNPs = 0.344/0.687 = 50%. 
There is another approach to calculate the percentage of unbound catechol groups in Cat-
MDBC/ESNPs based on ΔACat-MDBC = 0.28 ± 0.01, ΔACat-MDBC/ESNPs = 0.14 ± 0.01. According to 
Beer-Lambert Law A = εcl, in our experiment both light path l (1 cm) and ε570 are constant, 
therefore the concentration change (Δc) of Fe(III)-catechol complex from beginning to plateau 
equal to ΔA/(εl). In the previous titrations of dopamine hydrochloride, the equivalent of Fe3+: 
catechol = 1:1, therefore the ΔA ratio = 0.14/0.28 = 50% represents the percentage of unbound 
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